# NCT02071862 (NCT02071862)

> Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02071862
- Phase: PHASE1
- Status: COMPLETED
- Sponsor: Calithera Biosciences, Inc
- Conditions: Solid Tumors; Triple-Negative Breast Cancer; Non Small Cell Lung Cancer; Renal Cell Carcinoma; Mesothelioma; Fumarate Hydratase (FH)-Deficient Tumors; Succinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumors (GIST); Succinate Dehydrogenase (SDH)-Deficient Non-gastrointestinal Stromal Tumors; Tumors Harboring Isocitrate Dehydrogenase-1 (IDH1) and IDH2 Mutations; Tumors Harboring Amplifications in the cMyc Gene
- Interventions: CB-839; Pac-CB; CBE; CB-Erl; CBD; CB-Cabo
- Enrollment: 210
- Primary outcome: Safety and tolerability of CB-839: Incidence of adverse events

## Indexed commentary on NCT02071862 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 4 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct02071862